CN Patent
CN103732594A — 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
Assigned to Gillian Science · Expires 2014-04-16 · 12y expired
What this patent protects
本发明描述9-[(R>2-[[(S)-[[(S>1-(异丙氧羰基)乙基]氨基]苯氧基氧膦基]m(替诺福韦艾拉酚胺(tenofovir alafenamide))的半反丁烯二酸盐形式和使用替诺福韦艾拉酚胺半反丁烯二酸盐的抗病毒疗法(例如抗HTV和抗HBV疗法)。
USPTO Abstract
本发明描述9-[(R>2-[[(S)-[[(S>1-(异丙氧羰基)乙基]氨基]苯氧基氧膦基]m(替诺福韦艾拉酚胺(tenofovir alafenamide))的半反丁烯二酸盐形式和使用替诺福韦艾拉酚胺半反丁烯二酸盐的抗病毒疗法(例如抗HTV和抗HBV疗法)。
Drugs covered by this patent
- Emtriva (EMTRICITABINE) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.